exacerbations-tab

DUPIXENT SIGNIFICANTLY REDUCED
COPD EXACERBATIONS^1-3,a

When added to standard of care,
DUPIXENT significantly reduced the
annualized rate of moderate or

severe exacerbations

Annualized rate of moderate or severe
COPD exacerbations at Week 52
(primary endpoint)

Rate (exacerbations/year)

Adding DUPIXENT to
triple inhaled therapy
provided a

30%
reduction^b

Adding DUPIXENT to
triple inhaled therapy
provided a

34%
reduction^c

1.10

(n=471)

0.78

(n=468)

1.30

(n=465)

0.86

(n=470)

BOREAS Trial P<0.001

NOTUS Trial P<0.001

Placebo + SOC DUPIXENT + SOC

PATIENTS WITH A HISTORY OF ASTHMA WERE EXCLUDED
FROM THE BOREAS AND NOTUS TRIALS^2,3

Standard of care was triple inhaled therapy (LAMA+LABA+ICS).^1,4

^aModerate exacerbations were defined as exacerbations that resulted in treatment with a systemic glucocorticoid, an antibiotic agent, or both. Severe exacerbations were defined as exacerbations that led to hospitalization or an emergency medical care visit or that resulted in death.¹

^bRate ratio vs placebo: 0.71 (95% CI: 0.58, 0.86).¹

^cRate ratio vs placebo: 0.66 (95% CI: 0.54, 0.82).¹

COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; SOC, standard of care.

DUPIXENT SIGNIFICANTLY REDUCED COPD EXACERBATIONS1-3,a

PATIENTS WITH A HISTORY OF ASTHMA WERE EXCLUDED FROM THE BOREAS AND NOTUS TRIALS2,3

DUPIXENT SIGNIFICANTLY REDUCED
COPD EXACERBATIONS^1-3,a

PATIENTS WITH A HISTORY OF ASTHMA WERE EXCLUDED
FROM THE BOREAS AND NOTUS TRIALS^2,3